524629
Phosphatase Inhibitor Cocktail Set V, 50X
Phosphatase Inhibitor Cocktail Set V is a 50X cocktail of four serine/threonine and tyrosine phosphatase inhibitors.
Sign Into View Organizational & Contract Pricing
All Photos(1)
Phosphatase Inhibitor Mix Set V, Phosphatase inhibitor
Recommended Products
form
liquid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
protect from light
shipped in
wet ice
storage temp.
−20°C
General description
A cocktail of four phosphatase inhibitors for the inhibition of both serine/threonine and protein tyrosine phosphatases. Available as 1 ml or as a set of five 1 ml vials.
Application
Phosphatase Inhibitor Cocktail Set V, 50X has been used:
- as a supplement in the lysis buffer to dissociate metabolically activated one (MMe) bone marrow macrophages (BMDMs) for Western blot
- in radio-immunoprecipitation assay (RIPA) modified buffer to incubate cultured human umbilical vein endothelial cells (HUVECs) for western blot
- in lysis buffer to lyse cultured HUVECs for immunoprecipitation
- in wash buffer to wash the protein complexes
- as a component in 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) buffer to homogenize J774 cells to assess the effect of lipopolysaccharides (LPS) incubation on cytosolic phospholipase A2 (cPLA2) activity
Biochem/physiol Actions
Protein phosphorylation and dephosphorylation play a crucial role in signal transduction, controlling various cellular processes such as cell division, proliferation, and apoptosis. Protein kinases add a phosphate group to specific serine, threonine, or tyrosine residues, which alters the protein′s conformation and its ability to interact with ligands. Protein phosphatases then remove the phosphate group, restoring the protein to its original dephosphorylated state. When extracting phosphorylated proteins from cell and tissue lysates, it is of utmost importance to preserve their phosphorylation state.
Features and Benefits
- Convenient: formulations are ready-to-use, making them easy to use.
- Consistent: high-quality formulations ensure reliable and reproducible performance.
- Flexible: the cocktails are designed to target different categories of phosphatases, offering versatility in experimentation.
Components
Each vial contains 1 ml of aqueous solution with the following components:
- 250 mM Sodium Fluoride
- 50 mM ß-Glycerophosphate (Cat. No. 35675)
- 50 mM Sodium Pyrophosphate Decahydrate
- 50 mM Sodium Orthovanadate
Warning
Toxicity: Toxic (F)
Physical form
In H₂O.
Reconstitution
Following initial thaw, aliquot and freeze (-20°C) for long-term storage. Dilute 1:50 just prior to use.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Loss of transglutaminase 2 sensitizes for diet-induced obesity-related inflammation and insulin resistance due to enhanced macrophage c-Src signaling
Cell Death & Disease, 10(6), 439-439 (2019)
Lysophosphatidylinositols in inflammation and macrophage activation: altered levels and anti-inflammatory effects
Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids, 1863(12), 1458-1468 (2018)
Endothelial EphB4 maintains vascular integrity and transport function in adult heart
eLife, 8, e45863-e45863 (2019)
Science advances, 6(30), eabb4105-eabb4105 (2020-08-25)
Efforts at altering the dismal prognosis of pediatric midline gliomas focus on direct delivery strategies like convection-enhanced delivery (CED), where a cannula is implanted into tumor. Successful CED treatments require confirmation of tumor coverage, dosimetry, and longitudinal in vivo pharmacokinetic
Cancers, 14(6) (2022-03-26)
Prediction of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) remains challenging. Thus, we investigated whether resistant cancer cells that expand shortly after EGFR-TKI treatment would eventually cause the resistant phenotype. We generated two EGFR-mutant lung cancer cell
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service